In one paragraphArticle in Science translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
10 authors.
Zaofeng YangDepartment of Microbiology and Immunology, Columbia University, New York, NY 10032, USA.ORCID 0000-0003-4861-9729 Dylan L MariuzzaDepartment of Microbiology and Immunology, Columbia University, New York, NY 10032, USA.ORCID 0000-0002-9369-2514 Kenia de Los Santos-AlexisDepartment of Microbiology and Immunology, Columbia University, New York, NY 10032, USA.ORCID 0000-0002-3628-9796 Edward R BallisterDepartment of Microbiology and Immunology, Columbia University, New York, NY 10032, USA.ORCID 0000-0002-4478-2513 Olivia R RinghamDepartment of Microbiology and Immunology, Columbia University, New York, NY 10032, USA.
Nicholas ArpaiaDepartment of Microbiology and Immunology, Columbia University, New York, NY 10032, USA.ORCID 0000-0002-0657-0528 Funding
Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Anil K Rustgi · 1985 to 2026
$115.3MModulation of the tumor microenvironment with probiotic therapiesR01CA249160 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI ARPAIA, NICHOLAS, DANINO, TAL · 2020 to 2024
$3.0MEngineering immunotherapeutic probiotics to mitigate irAEU01CA247573 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI ARPAIA, NICHOLAS, DANINO, TAL · 2020 to 2024
$2.9MTreating colon cancer by regulating intestinal immunity through microbial metabolismR01CA259634 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ARPAIA, NICHOLAS · 2021 to 2025
$2.8MEngineered probiotic bacteria for colorectal cancer immunoprevention and interceptionUG3CA301294 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Nicholas Arpaia, Tal Danino · 2025 to 2026
$1.5MNCI NIH HHS P30 CA013696NCI NIH HHS R01 CA249160NCI NIH HHS R01 CA259634NCI NIH HHS U01 CA247573NCI NIH HHS UG3 CA301294
6 · The paper itselfAbstract
Achieving tumor-specific delivery and sustained activation of both cytotoxic and immune-modulating agents remains a critical challenge in chemoimmunotherapy. Here, a bacterial platform was engineered to combine enzyme/prodrug chemotherapy with immunotherapy, in which tumor-homing
Indexed as
ImmunotherapyNeoplasmsProbioticsAnimalsCell Line, TumorCytosine DeaminaseEscherichia coliFlucytosineFluorouracilHumansInterleukin-15MiceMice, Inbred C57BLProdrugsCytosine DeaminaseFlucytosineFluorouracilInterleukin-15Prodrugs
Identifiers
PMID42748218
PMCPMC13608007
What OpenQuestion holds
Textmetadata
Read underepoch 390